Like a self-assembling ‘Lego Death Star’, says lead researcher
Researchers have developed a simple and versatile method for making artificial anti-cancer molecules that mimic the properties of one of the body’s natural defence systems.
The chemists, led by Professor Peter Scott at the University of Warwick, UK, have been able to produce molecules that have a similar structure to peptides which are naturally produced in the body to fight cancer and infection.
Published in Nature Chemistry, the molecules produced in the research have proved effective against colon cancer cells in laboratory tests, in collaboration with Roger Phillips at the Institute for Cancer Therapeutics, Bradford, UK.
Artificial peptides had previously been difficult and prohibitively expensive to manufacture in large quantities, but the new process takes only minutes and does not require costly equipment. Also, traditional peptides that are administered as drugs are quickly neutralised by the body’s biochemical defences before they can do their job.
Reaad more . . .
The Latest on: Anti-cancer molecules
[google_news title=”” keyword=”Anti-cancer molecules” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-cancer molecules
- Faster aging might lead to getting cancer earlieron April 16, 2024 at 6:55 pm
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Faster aging might lead to getting cancer earlier Experts have known for a while that accelerated ...
- AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugateson April 12, 2024 at 7:15 am
This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.
- Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with pre-clinical dataon April 12, 2024 at 12:30 am
Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with pre-clinical data: Edinburgh, UK Friday, April 12, 2024, 13:00 Hrs [IST] Macomics Ltd, a ...
- Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024on April 11, 2024 at 2:17 am
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of ...
- Personalized anti-tumor vaccine enhances immunotherapy for liver canceron April 9, 2024 at 12:40 pm
Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the ...
- INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024on April 8, 2024 at 7:00 am
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast ...
- Opinion: The Next Generation of ADCs Will Improve Cancer Treatmenton April 7, 2024 at 10:56 pm
Researchers are working to optimize the properties of antibody-drug conjugates in order to maximize clinical efficacy while minimizing the risk of toxicities.
- Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meetingon April 7, 2024 at 5:00 pm
ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
- anti cancer associationon April 6, 2024 at 5:00 pm
Please read this Cookie Policy carefully as it contains important information on who we are and how we use cookies on our website. This policy should be read together ...
- RNA Molecules in Brain Nerve Cells Display Lifelong Stabilityon April 4, 2024 at 5:00 pm
Certain RNA molecules in the nerve cells in the brain last a life time without being renewed. Neuroscientists from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have now demonstrated that ...
via Bing News